<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00291798</url>
  </required_header>
  <id_info>
    <org_study_id>ABCSG-17</org_study_id>
    <nct_id>NCT00291798</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Endocrinotherapy of Breast Cancer (Mamma Carcinoma) With Exemestane</brief_title>
  <official_title>Neoadjuvant Endocrinotherapy of Mamma Carcinoma With Exemestane</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Austrian Breast &amp; Colorectal Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmacia Austria GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Austrian Breast &amp; Colorectal Cancer Study Group</source>
  <brief_summary>
    <textblock>
      The objective of the present clinical investigation is to determine whether hormonal therapy
      given preoperatively is able to reduce tumor size to an extent that facilitates
      breast-conserving procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open, prospective multicenter Phase II pilot trial investigates the efficacy of
      exemestane, 25 mg once daily over 4 months, in postmenopausal women with primary breast
      cancer, measured in terms of clinical response
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <completion_date>March 2009</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of remission</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity (WHO-grading)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of mastectomy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response of tumor subject to HER2-status</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>collection of disease free survival and overall survival</measure>
  </secondary_outcome>
  <enrollment>98</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>rate of remission</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically verified breast cancer (punch biopsy), established HER-2/neu status

          -  Postmenopausal patients (&gt; 1 year following outset of menopause and/or postmenopausal
             hormonal profile)

          -  Clinical staging: T2 (&gt; 3 cm), T3, T4a-c, N0-1

          -  Hormone receptor positivity, i.e. estrogen and/or progesterone receptor &gt; 10 fmol/mg
             cytosolic protein or ER-ICA-positive and/or PgR-ICA-positive. Positivity of +
             (low-grade) in one hormone receptor is only eligible in the presence of positivity in
             the other hormone receptor.

          -  no internal contraindication

          -  life expectation &gt; 6 month

          -  written informed consent

        Exclusion Criteria:

          -  premenopausal patients and patients with no clearly indicated menopausal status

          -  manifest second malignant tumor (except basalioma or in situ carcinoma of cervix
             uteri)

          -  uncontrolled internal disease i.e. diabetes mellitus, cardiac disease (NYHA III/IV)

          -  thromboembolic disease

          -  inflammatory mamma carcinoma

          -  existence of distant metastases

          -  former or simultaneously therapy with antioestrogens, aromatase inhibitors,
             cytostatics or radiotherapy

          -  corticosteroids before and during the study (except inhalant application)

          -  lack of compliance
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>59 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brigitte Mlineritsch, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Austrian Breast &amp; Colorectal Cancer Study Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital of Guessing</name>
      <address>
        <city>Guessing</city>
        <state>Burgenland</state>
        <zip>7540</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Hospital Klagenfurt, Surgery</name>
      <address>
        <city>Klagenfurt</city>
        <state>Carinthia</state>
        <zip>9026</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Hospital Wolfsberg</name>
      <address>
        <city>Wolfsberg</city>
        <state>Carinthia</state>
        <zip>9400</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Wiener Neustadt</name>
      <address>
        <city>Wiener Neustadt</city>
        <state>Lower Austria</state>
        <zip>2700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gynaegological Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Graz, Oncology</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital BHS Linz</name>
      <address>
        <city>Linz</city>
        <state>Upper Austria</state>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Linz</name>
      <address>
        <city>Linz</city>
        <state>Upper Austria</state>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paracelsus Medical University Salzburg, Oncology</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna, General Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanusch Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.abcsg.at</url>
  </link>
  <verification_date>February 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2006</study_first_submitted>
  <study_first_submitted_qc>February 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2006</study_first_posted>
  <last_update_submitted>September 18, 2006</last_update_submitted>
  <last_update_submitted_qc>September 18, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2006</last_update_posted>
  <keyword>pilot study</keyword>
  <keyword>exemestane</keyword>
  <keyword>endocrinotherapy</keyword>
  <keyword>mamma carcinoma</keyword>
  <keyword>neoadjuvant</keyword>
  <keyword>ABCSG</keyword>
  <keyword>17</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

